

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
l26 with l4	3

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼


Search:

L31

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** **Monday, July 14, 2003** [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L31</u>	l26 with l4	3	<u>L31</u>
<u>L30</u>	l26 same l4	3	<u>L30</u>
<u>L29</u>	L28 and l4	4	<u>L29</u>
<u>L28</u>	L27 with l26	50	<u>L28</u>
<u>L27</u>	lung or pneumo\$	103405	<u>L27</u>
<u>L26</u>	Rhino\$ with equine	381	<u>L26</u>
<u>L25</u>	rhinopnem\$	1	<u>L25</u>
<u>L24</u>	l22 same l4	4	<u>L24</u>
<u>L23</u>	L22 and l4	76	<u>L23</u>
<u>L22</u>	equine with influenza	587	<u>L22</u>
<u>L21</u>	equine with influenza	6	<u>L21</u>
<u>L20</u>	L19 and l4	27	<u>L20</u>
<u>L19</u>	L18 with l17	220	<u>L19</u>
<u>L18</u>	equine	8806	<u>L18</u>
<u>L17</u>	EHV or EIV	776	<u>L17</u>
<u>L16</u>	L15 same l2	16	<u>L16</u>
<u>L15</u>	copolymer with ema	1441	<u>L15</u>
<u>L14</u>	L13 and l4	20	<u>L14</u>
<u>L13</u>	L12 with l2	195	<u>L13</u>
<u>L12</u>	carbopol	7940	<u>L12</u>
<u>L11</u>	l10 and l4	9	<u>L11</u>
<u>L10</u>	L9 with l7	97	<u>L10</u>
<u>L9</u>	carbomer or EMA	9644	<u>L9</u>
<u>L8</u>	L7 and l1	23	<u>L8</u>
<u>L7</u>	antigen or vaccine or immunogen	121351	<u>L7</u>
<u>L6</u>	l4 and l1	6	<u>L6</u>
<u>L5</u>	l4 same l1	1	<u>L5</u>
<u>L4</u>	dna vaccine or gene delivery	6685	<u>L4</u>
<u>L3</u>	L2 same l1	19	<u>L3</u>
<u>L2</u>	adjuvant	77886	<u>L2</u>
<u>L1</u>	maleic anhydride with alkenyl	1389	<u>L1</u>

END OF SEARCH HISTORY



Day : Monday
Date: 7/14/2003
Time: 16:42:33

Application Number Information

Application Number: **09/912552**Examiner Number: **72603 / PRIEBE, SCOTT**

Assignments

Filing Date: **07/23/2001**Group Art Unit: **1632**Effective Date: **07/23/2001**Class/Subclass: **435/325.000**Application Received: **07/26/2001**Lost Case: **NO**Pat. Num./Pub. Num.: **/20020187553**

Interference Number:

Waiting for Response Desc.
Mail Final Rej.

Issue Date: **00/00/0000**Unmatched Petition: **NO**Date of Abandonment: **00/00/0000**L&R Code: Secrecy Code: **1**Attorney Docket Number: **3935.1US**Third Level Review: **NO**Secrecy Order: **NO**Status: **61 /FINAL REJECTION MAILED**Status Date: **05/08/2003**Confirmation Number: **4762**Oral Hearing: **NO**

Title of Invention: **PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY**

Bar Code	PALM Location	Location Date	Charge to Loc	Charge to Name	Employee Name	Location
<u>09912552</u>	<u>16C1</u>	07/14/2003	16G6	No Charge to Name	<u>NORFLEET,CASSIUS</u>	CM1/11/C 10

Appln
Info

Contents

Petition Info

Atty/Agent Info

Continuity Data

Foreign Data

Invent

Search Another: Application#

Search

or Patent#

Search

PCT /

Search

or PG PUBS #

Search

Attorney Docket #

Search

Bar Code #

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

WEST

Generate Collection

Print

L14: Entry 14 of 20

File: USPT

Oct 29, 2002

US-PAT-NO: 6472183

DOCUMENT-IDENTIFIER: US 6472183 B2

TITLE: Immunity against Actinobacillus pleuropneumoniae's RTX toxins APX

DATE-ISSUED: October 29, 2002

US-CL-CURRENT: 435/71.1; 424/184.1, 424/234.1, 424/235.1, 424/236.1, 435/243,
435/252.3, 435/252.8, 435/320.1, 435/471, 435/69.1, 435/69.3, 435/69.7, 536/23.1,
536/23.7

APPL-NO: 09/ 068086 [PALM]

DATE FILED: June 19, 1998

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY

APPL-NO

APPL-DATE

AU

PN 6314

November 2, 1995

PCT-DATA:

APPL-NO

DATE-FILED

PUB-NO

PUB-DATE

371-DATE

102(E)-DATE

PCT/AU96/00686 November 1, 1996 WO97/16532 May 9, 1997 Jun 19, 1998 Jun 19, 1998



US 20030003112A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0003112 A1**
Audonnet et al. (43) **Pub. Date: Jan. 2, 2003**(54) **PORCINE REPRODUCTIVE AND
RESPIRATORY SYNDROME VIRUS (PRRSV)
RECOMBINANT POXVIRUS VACCINE****Publication Classification**(51) **Int. Cl.⁷** **A61K 39/285; A61K 39/275;
C12N 7/00**(52) **U.S. Cl.** **424/232.1; 424/186.1; 435/235.1**(76) **Inventors: Jean-Christophe Audonnet, Lyon
(FR); Michel Bublot, Delmar, NY
(US); Jennifer Perez, Worcester, MA
(US); Philippe Baudu, Craponne (FR)**(57) **ABSTRACT****Correspondence Address:****Thomas J. Kowalski
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151 (US)**

What is described is a recombinant vector, such as a virus; for instance, a poxvirus, such as avipox virus, containing foreign DNA from porcine reproductive and respiratory syndrome virus. What are also described are immunological compositions containing the recombinant poxvirus for inducing an immunological response in a host animal to which the immunological composition is administered. Also described are methods of treating or preventing disease caused by porcine reproductive and respiratory syndrome virus by administering the immunological compositions of the invention to an animal in need of treatment or susceptible to infection by porcine reproductive and respiratory syndrome virus.

(21) **Appl. No.: 09/862,393**(22) **Filed: May 21, 2001****Related U.S. Application Data**(60) **Provisional application No. 60/206,655, filed on May 24, 2000.**

WEST

Generate Collection

Print

L16: Entry 4 of 16

File: USPT

Oct 9, 2001

DOCUMENT-IDENTIFIER: US 6300118 B1

TITLE: Plasmids comprising a genetically altered feline immunodeficiency virus genome

Detailed Description Text (7):

Typically, the concentration of virus in the vaccine formulation will be a minimum of 10.sup.6.0 virus particles per dose, but will typically be in the range of 10.sup.6.0 to 10.sup.8.0 virus particles per dose. At the time of vaccination, the virus is thawed (if frozen) or reconstituted (if lyophilized) with a physiologically-acceptable carrier such as deionized water, saline, phosphate buffered saline, or the like. An additional optional component of the present vaccine is a pharmaceutically acceptable adjuvant. Non-limiting examples of suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers such as Pluronic.RTM. (L121) Saponin; detergents such as Tween.RTM.-80; Quil.RTM. A, mineral oils such as Drakeol.RTM. or Marcol.RTM., vegetable oils such as peanut oil; Corynebacterium-derived adjuvants such as corynebacterium parvum; Propionibacterium-derived adjuvants such as Propionibacterium acne; Mycobacterium bovis (Bacillus Calmette and Guerin, or BCG); interleukins such as interleukin 2 and interleukin-12; monokines such as interleukin 1; tumor necrosis factor; interferons such as gamma interferon; combinations such as saponin-aluminum hydroxide or Quil.RTM. -A aluminum hydroxide; liposomes; iscom adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other derivatives; Avridine; Lipid A; dextran sulfate; DEAE-Dextran or DEAE-Dextran with aluminum phosphate; carboxypolymethylene, such as Carbopol.RTM.; ethylene maleic anhydride (EMA); acrylic copolymer emulsions such as Neocryl.RTM. A640 (e.g. U.S. Pat. No. 5,047,238); vaccinia or animal poxvirus proteins; subviral particle adjuvants such as orbivirus; cholera toxin; dimethyldioctadecylammonium bromide; or mixtures thereof.

Detailed Description Text (45):

Non-limiting examples of other suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers such as Pluronic.RTM. (L121) Saponin; detergents such as Tween.RTM.-80; Quil.RTM. A, mineral oils such as Drakeol.RTM. or Marcol.RTM., vegetable oils such as peanut oil; Corynebacterium-derived adjuvants such as corynebacterium parvum; Propionibacterium-derived adjuvants such as Propionibacterium acne; Mycobacterium bovis (Bacillus Calmette and Guerin, or BCG); interleukins such as interleukin 2 and interleukin-12; monokines such as interleukin 1; tumor necrosis factor; interferons such as gamma interferon; combinations such as saponin-aluminum hydroxide or Quil.RTM. -A aluminum hydroxide; liposomes; iscom adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other derivatives; Avridine; Lipid A; dextran sulfate; DEAE-Dextran or DEAE-Dextran with aluminum phosphate; carboxypolymethylene, such as Carbopol.RTM.; EMA; acrylic copolymer emulsions such as Neocryl.RTM. A640 (e.g. U.S. Pat. No. 5,047,238); vaccinia or animal poxvirus proteins; subviral particle adjuvants such as orbivirus; cholera toxin; dimethyldioctadecylammonium bromide; or mixtures thereof. The composition may also include a non-ionic detergent or surfactant, preferably a polyoxyethylene sorbitan monooleate such as a Tween.RTM. detergent, most preferably Tween.RTM.-80, i.e. polyoxyethylene (20) sorbitan monooleate.

WEST☐ Generate Collection

L16: Entry 5 of 16

File: USPT

Dec 21, 1999

DOCUMENT-IDENTIFIER: US 6004563 A

TITLE: Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same

Detailed Description Text (24):

Ethylene/maleic anhydride copolymer is another preferred adjuvant. Suitable ethylene/maleic anhydride copolymers useful in this invention are the linear ethylene/maleic copolymers such as EMA-31 (as produced by Monsanto Co., St. Louis, Mo.), a copolymer with approximately equal amounts of ethylene and maleic anhydride, having an estimated average molecular weight of about 75,000 to 100,000. These copolymers are water soluble, white, free-flowing powders having the following typical properties: a true density of about 1.54 g/mL, a softening point of about 170.degree. C., a melting point of about 235.degree. C., a decomposition temperature of about 274.degree. C., a bulk density of about 20 lbs/ft.sup.3, and a pH (1% solution) of 2.3.